Hyderabad: Vivimed Labs, a speciality chemical and Home and Personal Care (H&PC) company, is likely to take over two companies in the US and Europe. The Hyderabad-based company, which has bought UK-based James Robinson last month, is currently in talks with the target firms, and the acquisition is almost certain. The Rs 140-crore company (2006-07) believes that an inorganic growth path is the best way, given the global potential for H&PC products. Vivimed, which is a eligible supplier of ingredients to over 30 global personal care products, is planning to transfer the manufacturing of James Robinson''s products to India. The global H&PC market is pegged at $275 billion, with 12 per cent growth per annum. Australia and Asia have a 1 per cent share in this, while India''s share is below 0.5 per cent and there is lot of scope for a middle-tier company like Vivimed.
In the speciality pharma division, which pools in 30 per cent of the revenue, Vivimed is working on anti-TB and anti-hypertension drugs in addition to its existing anti-cancer range. By 2010, its revenues will come equally from H&PC and speciality pharma. Vivimed is hoping to clock revenue of Rs 195 crore, with about Rs 20 crore as net profit this fiscal year.
In the speciality pharma division, which pools in 30 per cent of the revenue, Vivimed is working on anti-TB and anti-hypertension drugs in addition to its existing anti-cancer range. By 2010, its revenues will come equally from H&PC and speciality pharma. Vivimed is hoping to clock revenue of Rs 195 crore, with about Rs 20 crore as net profit this fiscal year.
No comments:
Post a Comment